Virovet

company

About

ViroVet is a pioneering company.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
€6M
Industries
Biotechnology,Pharmaceutical,Veterinary
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viral diseases cost producers billions every year in losses and threaten the world supply of animal protein.



The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases.



It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry.



ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€6M
Virovet has raised a total of €6M in funding over 2 rounds. Their latest funding was raised on May 28, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 28, 2020 Series B €6M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Virovet is funded by 2 investors. Fonds Vives II (University of Louvain, UCL) and Biotech Fund Flanders are the most recent investors.
Investor Name Lead Investor Funding Round
Fonds Vives II (University of Louvain, UCL) Series B
Biotech Fund Flanders Series B